Advertisement
Advertisement
U.S. Markets close in 5 hrs 13 mins
Advertisement
Advertisement
Advertisement
Advertisement

Revolution Medicines, Inc. (RVMD)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
26.97-0.36 (-1.32%)
As of 10:43AM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close27.33
Open27.39
Bid26.93 x 1100
Ask27.15 x 1400
Day's Range26.39 - 27.39
52 Week Range21.78 - 56.18
Volume32,175
Avg. Volume516,550
Market Cap1.981B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-21.25
Earnings DateAug 09, 2021 - Aug 13, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est33.00
  • Insider Monkey

    Hedge Funds Are Crazy About Revolution Medicines, Inc. (RVMD)

    A whopping number of 13F filings filed with U.S. Securities and Exchange Commission has been processed by Insider Monkey so that individual investors can look at the overall hedge fund sentiment towards the stocks included in their watchlists. These freshly-submitted public filings disclose money managers’ equity positions as of the end of the three-month period […]

  • GlobeNewswire

    Revolution Medicines to Present New Preclinical Data from RAS(ON) Inhibitor Programs at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

    Company Invited to Deliver Oral Presentation in “Drugging Difficult Targets” Plenary SessionREDWOOD CITY, Calif., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted drugs to inhibit frontier targets that drive and sustain RAS-addicted cancers, today announced that new preclinical data from several of the company’s RAS(ON) inhibitor programs will be reported in an invited oral presentation during

  • GlobeNewswire

    Revolution Medicines to Participate in 3rd Annual RAS-Targeted Drug Development Summit

    Company’s Scientific Leadership to Highlight Key Findings from Ongoing RAS(ON) Inhibitor ProgramsREDWOOD CITY, Calif., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted drugs to inhibit frontier targets that drive and sustain RAS-addicted cancers, today announced that the company will participate in the upcoming 3rd Annual RAS-Targeted Drug Development Summit being held September 21-23, 2021. S

Advertisement
Advertisement